MedPath

Post marketing study of sofosbuvir and ledipasvir for genotype 1 hepatitis C virus infectio

Not Applicable
Conditions
Hepatitis virus infection
Registration Number
JPRN-UMIN000023271
Lead Sponsor
Wakayama Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1) pregnant woman 2) decompensated cirrhosis 3) severe renal dysfunction (<eGFR30)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Sustained virological response at 12 weekes after the end of therapy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath